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Background: Cluster of differentiation 14 (CD14) functions as a co-receptor for Toll-like receptor (TLR)-4 and
myeloid differentiation factor (MD)-2 in detecting bacterial lipopolysaccharide. Together, these complexes promote
the phagocytosis and digestion of Gram-negative bacteria, and initiate immune responses. To date, much of our
understanding of CD14 function during Gram-negative bacterial inflammation comes from studies on mouse
knockout models and cell transfection. To identify the effect of CD14 knockdown in this process in large livestock
animals, we established a mouse model expressing bovine CD14 short hairpin (sh) RNA. shRNA fragments targeting
bovine CD14 were screened by co-transfection in HEK 293 cells, and the most effective CD14 shRNA fragment was
cloned into the eukaryotic expression vector pSilencer4.1-CD14 shRNA-IRES (internal ribosome entry site) and
transferred into mouse zygotes by pronuclear microinjection to obtain transgenic mice. Expression of the enhanced
green fluorescent protein (EGFP) reporter and genes related to the TLR4 signaling pathway was detected by
immunohistochemistry (IHC) and quantitative polymerase chain reaction (PCR), respectively.
Results: One effective shRNA fragment (shRNA-674) targeting bovine CD14 was obtained, the sequence of which
was shown to be conserved between cows, buffalos, sheep, and humans. Thirty-seven founder pups were obtained
by pronuclear microinjection, of which three were positive for the transgene. In the F1 generation, 11 of 33 mice
(33%) were positive for the transgene as detected by PCR. IHC analysis detected exogenous EGFP expression in the
liver, kidney, and spleen of transgenic F1 mice, indicating that they were chimeric. The expression of endogenous
CD14 mRNA in the heart, liver, spleen, lung, and kidney of transgenic F1 mice was decreased 8-, 3-, 19.5-, 6-, and
11-fold, respectively. The expression patterns of endogenous MD-2, TLR4, interleukin-6 and tumor necrosis factor-α
genes in transgenic mice also varied.
Conclusions: This study confirms that transgenic mice expressing bovine CD14 shRNA can be generated by
pronuclear microinjection, and demonstrates inhibited endogenous mouse CD14 expression that alters gene
expression related to the TLR4 signaling pathway.
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CD14 is a 55 kDa glycoprotein expressed mainly on the
surface of monocytes, macrophages, and granulocytes
[1], which plays a crucial role in the inflammatory re-
sponse to lipopolysaccharide (LPS) [2-4]. Currently, LPS-
induced cellular activation is thought to occur through
signal complexes comprised of CD14 and either myeloid* Correspondence: xiangpingli@163.com; ardsshi@163.com
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[5-7]. LPS binding to these complexes facilitates activation
of the TLR4/nuclear factor (NF)-κB inflammatory path-
way, ultimately leading to the production of proathero-
genic cytokines including tumor necrosis factor alpha
(TNF-α), interleukin-6 (IL-6), and IL-1 [8-11].
Strategies aimed at inhibiting the expression of TLR4
complex genes have been used to analyze their contribution
to inflammatory reactions [12-14]. In addition to inhibiting
TLR4 expression, many CD14-deficient mice have also
been established by CD14 knockout strategies [15-17].
When infected by live Gram-negative bacteria or LPS,
CD14-deficient mice demonstrate reduced bacteremia andis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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CD14 may limit the release of a broad range of inflamma-
tory mediators, and prevent rapid bacterial dissemination
following infection by Gram-negative bacteria [1,19-22].
Numerous approaches using monoclonal antibodies,
small molecule antagonists, and RNA interference have
demonstrated that inhibiting LPS signals through
lipopolysaccharide-binding protein, CD14, MD-2, and
TLR4 reduce the release of inflammatory cytokines
[20,23-26]. For instance, small interfering (si) RNA target-
ing CD14 in the mouse cell line RAW264.7 was found to
inhibit the release of TNF-α, macrophage inflammatory
protein-2, IL-6, and the production of nitric oxide following
exposure to LPS [27]. Thus far, most of our understanding
about the role of CD14 during Gram-negative bacterial in-
flammation comes from studies of mouse knockout models
or mouse and human immune cells. However, because of
the serious harm caused by bacterial infections such as mas-
titis and Brucella in large livestock animals and huge result-
ant losses to the breeding industry, it is essential to establish
knockout models of such animals to investigate the CD14
role in LPS-induced inflammation. This would also be of
benefit in the development of a practical and effective meas-
ure to prevent bacterial infection in livestock. Based on our
previous discovery of the effect of CD14 down-regulation in
buffalo monocytes/macrophages [28], the present study
aimed to establish a transgenic mouse model to express bo-
vine CD14 short hairpin (sh) RNA, and to determine the ef-
fect of endogenous mouse CD14 down-regulation on gene
expression of the mouse TLR4 signaling pathway.
Results
Screening of shRNA sequences targeting bovine CD14
Given the importance of CD14 in LPS signaling, we first
sought to screen shRNA sequences for their ability to
inhibit bovine CD14 expression in vitro. Using ABI siRNA
online software (http://www.ambion.com), three different
sites of the bovine CD14 mRNA sequence (GenBank
Accession No. NM_174008.1) were used to design three
CD14 shRNA sequences (shRNA-279, −326, and −674).
CD14 shRNA lentiviral expression vectors with human
U6 promoters were constructed (pSicoR-CD14 shRNA-
279/326/674), and lentiviral particles were produced
using the calcium-phosphate method, with titers reaching
1 × 107 (data not shown). Lentiviral particles expressing
bovine CD14 shRNA were used to infect HEK 293 cells
expressing CD14 at a multiplicity of infection (MOI) of
100, using a non-infected cell line as blank control, the
scrambled shRNA as negative control. The infected cells
were harvested 72 h after infection and total RNA was
extracted for quantitative reverse-transcription polymer-
ase chain reaction (qRT-PCR) analyses. As expected, cells
infected with the shRNA-negative control showed no
reduction in CD14 expression (Figure 1A). Comparedwith scrambled shRNA-1864, shRNA-279 and shRNA-
326 fragments were also unable to reduce bovine CD14
expression. However, the shRNA-674 fragment signifi-
cantly inhibited CD14 mRNA expression in vitro (p < 0.01)
(Figure 1A). shRNA-674 nucleotides were highly conserved
between cows, sheep, buffalos, and humans, indicating that
this shRNA fragment could potentially be used in related
research of multiple species.
To confirm if the shRNA-674 fragment also reduced
expression of the CD14 protein, we performed western
blot analysis. At two different MOIs, the intracellular
expression of shRNA-674 completely abolished CD14
protein expression (Figure 1B), which was consistent with
RT-PCR analysis.
shRNA transgenic mice demonstrated reduced CD14
expression
We next determined the effects of the shRNA-674 frag-
ment on CD14 expression in vivo. To avoid the biological
safety problems of lentiviruses, the shRNA-674 fragment
was inserted into the eukaryotic shRNA expression
vector pSilencer™4.1-CMV neo. Internal ribosome entry
site (IRES) elements were then ligated with the vector to
construct the pSilencer4.1-CD14 shRNA-674-IRES plas-
mid (Figure 1). This plasmid was linearized with Nhe I
digestion and microinjected into the pronucleus of fertil-
ized eggs from FVB mice to create CD14 shRNA trans-
genic mice. After transferring two-cell stage embryos into
pseudo-pregnant females, a total of 37 founder pups were
obtained. Transgene integration in F0 offspring was ana-
lyzed by amplifying EGFP and neo genes that were both
amplified in three founder mice (8.1%): one male (11#)
and two females (22#, 32#) that were regarded as trans-
genic. Within the F1 generation (wild-type mouse with
transgenic F0 mouse cross), 33 mice were born, of which
11 were found to be transgenic (33.3%; data not shown).
In the 11 transgenic F1 mice, 3 was offspring of 11# F0
mouse, 5 and 3 were offspring of 22# and 32# mouse
respectively. Three of the 33 F1 mice were selected for
Southern blot analysis to confirm the PCR data. Two
(lane2, 4, offspring of 22#, 32# respectively) were transgenic
while the third was not (lane3, offspring of 11#) (Figure 1E).
These findings were consistent with PCR results (data not
shown).
To further characterize the transgene insertion, organs
of F1 transgenic mice (offspring of 22
#) were analyzed
for eGFP expression by confocal microscopy. This pro-
tein was shown to be expressed in the liver, kidney, and
spleen tissue of all transgenic mice, with the highest
expression detected in the spleen. However, eGFP
expression was absent from heart and lung tissues. The
expression pattern was similar in both male and female
mice (Figure 2). Together these data demonstrated that
the transgenic mice were chimeric.
Figure 2 The immunohistochemistry results of eGFP expression in tissues of CD14 shRNA transgenic mice under confocal microscopy.
Upper row: spleen; Middle row: liver; Lower row: kidney. Left parts were male samples, and right were female samples.
Figure 1 Screening of bovine CD14 shRNA and construction of its eukaryotic expression vector. A. Effect of designed bovine CD14
shRNAs was detected by qRT-PCR analysis. The lentiviral particles expressing CD14 shRNAs were used to infect HEK 293 cells expressing bovine
CD14, non-infected cell line as a blank control, the scrambled shRNA as negative control. The values for columns with different letters represent
statistically significant differences, p < 0.01. B. The inhibition effect of CD14 shRNA-674 fragment was confirmed by western blot analysis. HEK 293
cells stably expressing bovine CD14 were infected by shRNA-674 lentivirus at two different MOIs (lane1, 2), the negative control was HEK 293 cells
stably expressing bovine CD14 (lane 3). C. Identification of the pSilencer™4.1-CD14-IRES recombinant plasmid. M: 1 kb Marker; Lane1: pSilencer™4.1-
CD14shRNA-IRES plasmid: Lane2: pSilencer™4.1-CD14shRNA-IRES plasmid digested by SspI enzyme; Lane3: pSilencer™4.1-CD14shRNA-IRES plasmid
digested by HpaI and BamHI enzyme. D. Map of pSilencer™4.1-CD14 shRNA-IRES vector. E. Confirmation of F1 generation transgenic mice by Southern
blot analysis. Three F1 mice were selected, among them, two (offspring of 22
#, 32#) were transgenic while the third was not (offspring of 11#) by
RT-PCR analysis. The positive control was pSilencer™4.1-CD14 shRNA-674-IRES plasmid. M: Marker; Lane 1: positive control; Lane 2: offspring of 22#
mouse; Lane 3: offspring of 11# mouse; Lane 4: offspring of 32# mouse.
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the expression of endogenous CD14 mRNA in vivo, we
used qRT-PCR to analyze the relative expression of CD14
expression in tissues of F1 transgenic mice (offspring of
22#). Compared with non-transgenic mouse RNA sam-
ples, the expression of endogenous CD14 mRNA in the
heart, liver, spleen, lung, and kidney tissues of transgenic
mice was reduced 8-, 3-, 19.5-, 6-, and 11 fold, respectively
(Figure 3). Thus, the expression of endogenous CD14
mRNA was inhibited in transgenic mice.
We next examined the expression pattern of genes in
the TLR4 signaling pathway. TLR4 demonstrated a sig-
nificantly increased expression level in the heart and
liver of CD14 shRNA transgenic mice compared with
wild-type mice (p < 0.05), although there were no sig-
nificant differences in expression in the spleen, lung,
or kidney between transgenic and wild-type mice.
MD-2, TNF-α, and IL-6 transcripts showed similar ex-
pression patterns, except for the kidney, with signifi-
cantly increased expression in the heart, liver, and
lung (p < 0.05), and significantly lower expression in
the spleen (p < 0.05) compared with wild-type mice. Ex-
ogenous neo expression showed the same pattern as that
of MD-2 and IL-6 (Figure 3) but with greater differences
between transgenic and wild-type mice. Together, these
results revealed the successful generation of a mouse
model expressing bovine CD14 shRNA, and indicated thatFigure 3 Expression of endogenous CD14, TLR4, MD-2, TNF-α, and IL-6
assess target gene expression in the heart, liver, spleen, lung, and kidney o
Different letters represent statistically significant differences, p < 0.05.the inhibition of exogenous CD14 expression altered the
expression levels of genes in the TLR4 signaling pathway
in vivo.
Discussion
Several studies have previously demonstrated that CD14
plays a crucial role in the inflammatory response to LPS
[2-4]. In the CD14-dependent signaling pathway, CD14
binds to LPS and facilitates activation of the TLR4/NF-κB
inflammatory pathway [28]. Upstream inhibition of the
bacterial LPS/TLR4/CD14-mediated inflammation path-
way has been proven to be an effective therapeutic ap-
proach for attenuating dysfunctional immune activation
[20,29]. However, very few studies have investigated the
role of CD14 in LPS-induced inflammation in large live-
stock animals such as sheep, cows, and buffalos. Never-
theless, this is of particular importance because of the
multiple reproductive and veterinary problems associated
with these species, and the need to develop a practical
and effective measure to prevent bacterial infections in
livestock.
We previously found that knockdown of endogenous
CD14 had clear regulatory effects on the signal transduc-
tion of TLR4 after stimulation with LPS in buffalo
monocyte/macrophages in vitro [28]. To determine if
CD14 knockdown had similar effects in large livestock
animals in vivo, it is first necessary to establish a mousemRNA in CD14 shRNA transgenic mice. qRT-PCR was used to
f F1 transgenic mice. Wild-type mice were used as negative controls.
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would provide basic data about CD14 knockdown on
animal development, gene expression in the CD14-
dependent signaling pathway, and most importantly on
toxicity experiments. Future work could then build on
these data and establish a larger animal model with the
aim of developing novel therapeutic interventions to in-
flammatory diseases caused by Gram-negative bacteria.
Conclusions
We successfully generated a mouse model expressing
bovine CD14 shRNA by pronuclear microinjection. More-
over, we showed that the inhibited expression of exogen-
ous CD14 shRNA altered the expression levels of some
genes in the TLR4 signaling pathway in transgenic mice.
Methods
All experiments and protocols were performed in strict
accordance with the Guiding Principles for the Care and
Use of Research Animals from the Guangxi University
Committee on Animal Research and Bioethics, the com-
mittee explicitly approved the animal study.
Reagents and antibodies
All chemicals used in this study were purchased from
Sigma-Aldrich (St. Louis, MO), unless otherwise stated.
TCM-199 powder was purchased from Gibco BRL (Paisley,
Scotland, UK), and Dulbecco’s modified Eagle’s medium
was purchased from Hyclone (Logan, UT). The pSilen-
cer4.1 vector (Life technology, USA), the pEF-EGFP-IRES-
neo-SV40-polyA vector, and the pSicoR-GFP vector were
generated or maintained by our laboratory. The anti-
buffalo CD14 primary antibody was kindly provided by Dr.
Wang Fengyang (Hainan University, Haikou, China).
Bovine CD14 cloning and expression vector construction
The bovine CD14 coding sequence fragment (1,340 bp)
was cloned by RT-PCR, confirmed by sequencing, and
used to construct the pDsRed1-N1-bovine CD14 fusion
vector by inserting the CD14 fragment into the SalIandTable 1 The designed shRNA sequences of the bovine CD14 g
Name Duplexes of DNA coding specific sh






Scrambled shRNA-1864 S 5’-CTCGAGCCGGCCTAAGGTTAAGTCG
AS 5’-GCGGCCGCCAAAAAACCTAAGGTSacII sites. This plasmid was then transfected into HEK
293 cells using Lipofectamine® LTX reagent according
to the manufacturer’s instructions, and cell lines that
stably expressed bovine CD14 were selected using G418
selection.shRNA design and synthesis
Using ABI siRNA online software (http://www.life
technologies.com/cn/zh/home/life-science/rnai/synthetic-
rnai-analysis/ambion-silencer-select-sirnas/silencer-select-
sirna.html?ICID=search-am16704), three different regions
of the bovine CD14 mRNA sequence (GenBank Accession
No. NM_174008.1) were used to design CD14 shRNA
sequences, which were synthesized by Nanjing GenScript
Co. (Nanjing, China). A universal shRNA scramble con-
trol (NC) sequence was also purchased (Cat. No. 1864,
Open Biosystem, Huntsville, AL). The 71 bp oligonucleo-
tide sequence of each shRNA fragment followed the same
pattern: 5′-Xho I-CCGG-shRNA (sense strand)-TTGAA
GAGA (loop structure)-shRNA (antisense strand)-TTTT
TT-Not I-3′ (Table 1). shRNA lentiviral expression vectors
were constructed by inserting the synthesized shRNA
fragments into the pSicoR-GFP vector (Addgene, USA)
after digestion with Xho I and Not I. These vectors are
referred to as pSicoR-GFP-CD14 shRNA (279/326/674)
and scrambled shRNA-1864. The constructed shRNA
lentiviral vectors were confirmed by restriction enzyme
digestion and sequencing.Lentivirus packaging and titer determination
Lentiviral particles were produced as previously de-
scribed [30]. The pSicoR-GFP CD14 shRNA vector was
co-transfected into 293 T cells with vesicularstomatitis
virusG (VSVG) and NRF plasmids using the calcium-
phosphate method [30]. Supernatant was harvested
48–72 h after transfection, centrifuged at 2,000 rpm for
10 min at 4°C to remove cellular debris, and filtered
through a 0.45 μm membrane. Viral titers were deter-
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shRNA sequences were screened by infecting HEK293
cells expressing bovine CD14 with lentiviral particles
containing different CD14 shRNAs. Cells were harvested
72 h after infection and total RNA was extracted using
Trizol reagent. The inhibition effects of each shRNA
sequence on CD14 were quantified using qRT-PCR and
western blot analysis.
For qRT-PCR analysis, total RNA was extracted with
Trizol (Invitrogen, USA), digested with DNaseI (Tiangen,
Beijing) to remove contaminating genomic DNA, then
reverse transcribed into cDNA using AMV reverse tran-
scriptase (Takara, Dalian) according to the manufacturer’s
instructions. cDNA was diluted to 100 ng/μL for subse-
quent TaqMan quantitative PCR analysis (ABI 7500) using
the probes and primers listed in Table 2. PCR conditions
were: 94°C for 30 s, followed by 40 cycles of 94°C for 15 s
and 60°C for 30 s. Duplicate PCR experiments were per-
formed for each transcript. The comparative Ct method
was used for the relative quantification of target gene ex-
pression levels (ABI Prism Sequence Detection System).
The histone H2a gene was used for normalization. Within
the log-linear phase region of the amplification curve,
fold-changes in the relative mRNA expression of the tar-
get gene were determined using the formula 2-ΔΔCT.Table 2 The primers used in the paper
Gene Primer sequences






EGFP Forward: 5’- ACGTAAACGGCCACAAGTTC -3’
Reverse: 5’- GATCTTGAAGTTCACCTTGATGC -3’













Reverse: 5’-GGAGGGGCCGGACTCATCGT-3’Western blot analysis was performed using standard
protocols. The primary antibody was a rabbit anti-bovine
CD14 polyclonal (1:200) (a gift from Dr. Fengyang Wang),
and the secondary antibody was horseradish peroxidase-
conjugated goat anti-rabbit IgG (Tiangen Biotech, Beijing,
China; 1:1,000). Bovine CD14 shRNA-674 lentivirus was
used to infect HEK 293 cells stably expressing bovine
CD14 at two different MOIs, 50 and 100 respectively. The
cells were harvested at 72 h after infection, HEK 293
cells stably expressing bovine CD14 were used as negative
controls.Construction of CD14 shRNA-674 eukaryotic expression
vector
The pSilencer™4.1-CMV neo and pSicoR-CD14 shRNA-
674 plasmids were first digested with BamHI and Hin-
dIII, respectively, then the CD14 shRNA-674 fragment
was inserted into the pSilencer™4.1-CMV neo backbone
to construct the pSilencer™4.1-CD14 shRNA plasmid.
The IRES fragment was amplified by PCR using pEF-
EGFP-IRES-neo-SV40-polyA vector as template and
primer sequences listed in Table 2. It was then ligated
with pSilencer™4.1-CD14 shRNA-674 to construct the
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transfection experiments.
Generation and detection of transgenic mice
The pSilencer™4.1-CD14 shRNA-674-IRES cassette was
digested with Nhe I (Takara, Dalian, China) and purified
by gel extraction (Qiagen, USA). The purified fragment
was then microinjected into the pronucleus of 200 fertil-
ized FVB mice eggs, which were implanted into pseudo-
pregnant FVB females. All mice were housed at the
transgenic mouse facility of Cyagen Biosciences Inc.
(Guangzhou, China).
DNA purified from the tails of F0 offspring mice was
used to screen for transgene integration by the PCR amp-
lification of EGFP and neo (Table 2). Transgenic F0 mice
were crossed with wild-type mice to obtain an F1 gener-
ation that was also screened using PCR amplification as
above. Three of the 33 F1 mice were selected for Southern
blot analysis to confirm PCR data using the DIG High
Prime DNA Labeling and Detection Starter kit II (Roche,
USA). The probe was complemented with the neo frag-
ment by digesting the pSilencer4.1-CD14shRNA-IRES
plasmid with Nco I and Eag I. The positive control was
pSilencer™4.1-CD14 shRNA-674-IRES plasmid.
Transgene expression analysis
The expression of eGFP in tissues of F1 transgenic mice
was assayed by confocal microscopy (LSM 510, Zeiss,
Oberkochen, Germany). Briefly, 10-μm-thick cryostat
sections from snap frozen tissues were prepared and
fixed with 4% paraformaldehyde. Specimens were visual-
ized using an Olympus BX61 microscope, and digital
pictures were acquired with a CCD camera.
The relative expression of CD14, MD-2, TLR4, IL-6,
TNF-α, and neo mRNA in the heart, liver, spleen, lung,
and kidney of F1 transgenic mice was assessed by SYBR®
Green qRT-PCR; tissues of wild-type mice were used as
a negative control. ACTB and histone H2a were used as
internal control genes (Table 2), and non-transcribed
RNA samples served as an RT-minus control. The ex-
pression level of each target gene was calculated using
the 2-ΔΔCT formula as above.
Statistical analysis
qRT-PCR mRNA expression data were analyzed using
SPSS16.0 and Excel 2003 to statistically process multiple
samples. Single-factor analysis of variance and the q-test
were used for pairwise comparisons. A P-value of less
than 0.05 was considered to be significant.
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